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Abstract
Objective: Microalbuminuria (MA) is related to cardiovascular disease both in diabetic patients and
non-diabetic subjects.
Design: We investigated whether a polymorphism near the promoter region of the IGF-I gene was
related to the development of MA.
Methods: For this study, 1069 participants of the Rotterdam study were selected (440 participants
with an abnormal glucose tolerance (AGT), 220 participants with type 2 diabetes and 254 subjects
with pre-diabetes, and 595 subjects with a normal glucose tolerance (NGT).
Results: 787 subjects were carriers of the wild type IGF-I genotype (73.6%) and 282 subjects were
variant carriers (26.4%) of this IGF-I gene polymorphism. Compared to subjects with NGT the risk
for microalbuminuria was higher (Odds Ratio (OR): 3.1 (95% CI: 1.2–7.7); P ¼ 0.02) in variant car-
riers with AGT than in carriers of the wild type of this IGF-I gene polymorphism (OR: 2.2 (95% CI:
1.2 –4.0); P ¼ 0.009). Compared with wild type carriers with AGT, the relative risk for MA was unad-
justed and non-significantly increased in variant carriers with AGT (1.6; 95% CI: 0.8 –2.9). However,
after adjustment for possible confounding factors (age, gender, mean blood pressure, fasting insulin,
fasting glucose and smoking) this risk became significant (OR: RR 2.1; 95% CI:1.1–4.4; P ¼ 0.04).
Conclusions: In subjects with AGT, a higher risk for MA was observed in variant carriers than in car-
riers of the wild type genotype of this IGF-I gene polymorphism. Since MA is primarily associated with
cardiovascular disease in subjects with AGT, our study suggests that variant carriers have a higher
risk for cardiovascular disease than carriers of the wild type when they develop an AGT.
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Introduction
The presence of microalbuminuria (MA) may be a
marker of generalized vascular endothelial dysfunction
reflecting generalized vascular disease (1, 2). Develop-
ment of MA is associated with glycaemic control, blood
pressure, smoking, and male gender (3, 4). MA may pre-
cede type 2 diabetes, occurring in parallel with the meta-
bolic syndrome and its components, obesity and
hypertension (1). MA is also considered to be a marker
for diabetic nephropathy in type 2 diabetes (5–7).
The insulin-like growth factor-I (IGF-I) system exerts
multiple physiologic effects on the vasculature through
both endocrine and autocrine/paracrine mechanisms
(8). Both macrovessel and microvessel endothelial
cells express IGF-I receptor (IGF-IR; 9). The expression
of IGF-I in endothelial cells is low and might reflect
mainly IGF-I sequestered from serum (10). IGF-I has
been also implicated in the development of cardiovas-
cular disease (8, 11–13).
IGF-I has been further implicated in the development
of diabetic nephropathy (14, 15). IGF-I bioactivity is
regulated by genetic and non-genetic factors like
growth hormone, nutrition and insulin (16). In
humans, a cytosine–adenine (CA)n polymorphism in
the promoter region of the IGF-I gene has been ident-
ified (17). Studies of other genes have suggested that
polymorphic CA repeats in the promoter region of a
gene, affects transcription activity of a gene (18). This
polymorphism has thus the potential to influence
directly the expression of IGF-I in the body (19).
Circulating IGF-I levels are often used as a substitute
for tissue IGF-I bioactivity due to the lack of in vivo
methods to measure the latter. However, determi-
nations of circulating total IGF-I levels by radio-
immunoassays may be especially problematic in
pathological conditions, due to interferences of
IGF-binding proteins. As a consequence, circulating
IGF-I levels may not adequately reflect the IGF-I
bioactivity. An alternative approach may be genetic
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association studies. In these studies, genetic variants
can be treated as risk factors that cannot be influenced
by secondary factors such as hypertension or hyper-
glycemia, unless these phenotypes are in the causal
pathway. This opens the opportunity to characterize
on a genetic basis, individuals who are at risk for
MA. The aim of the present study was to investigate
whether a polymorphism near the promoter region of
the IGF-I gene was related to the development of MA.
Subjects and methods
Study population
All subjects included in the present study were partici-
pants of the Rotterdam Study. The Rotterdam Study is a
single-center prospective follow-up study in which all
residents aged 55 years and over of the Rotterdam
suburb Ommoord were invited to participate. The
Medical Ethics Committee of Erasmus Medical Center
Rotterdam approved the study and written informed
consent was obtained from all participants. The aim
of the Rotterdam study and the design of the study
has been described previously (20). The baseline exam-
ination of the Rotterdam Study was conducted between
1990 and 1993. A total of 7983 participants (response
rate 78 percent) were examined.
Because of practical and financial reasons, only a
proportion of the Rotterdam Study (n ¼ 1069) under-
went a fasting glucose tolerance test. From this group
we selected our cases and controls for a case-control
study in which we assessed the relation between both
IGF-I genotypes, glucose tolerance and albuminuria
(21). Criteria for the present study were age younger
than 75 years, no use of anti-epileptics, corticosteroids,
hormonal replacement therapy, cytostatics and people
with dementia. After blood was drawn from the partici-
pants after an overnight fast, participants underwent
an oral glucose tolerance test with 75 g glucose.
Diabetic patients who were treated with anti-diabetic
medication did not undergo a glucose tolerance test.
Therefore, post load glucose measurements were only
available for persons not using anti-diabetic
medication. For the oral glucose tolerance test blood
was drawn after 2 h. Normal glucose tolerance (NGT)
was defined as fasting glucose below 6.1 mmol/l and
2-h post load below 7.8 mmol/l. Individuals with high
glucose levels not meeting criteria for diabetes, but
were too high to be considered normal were diagnosed
as having prediabetes. Prediabetes includes persons
with impaired fasting glucose (IFG) and/or impaired
glucose tolerance (IGT). IFG was defined as fasting
glucose between 6.1 and 7.0 mmol/l and IGT as a 2-h
post load glucose between 7.8 and 11.1 mmol/l.
A diagnosis of diabetes mellitus was made if subjects
were treated for diabetes or had a fasting glucose level
of 7.0 mmol/l or above and/or a 2-h post load glucose
of 11.1 mmol/l or above (22). All individuals meeting
criteria for diabetes or prediabetes were to be considered
as subjects with an abnormal glucose tolerance (AGT).
To determine insulin sensitivity we used the homeo-
stasis model assessment (HOMA)(23).
Measurements
A questionnaire was used to collect data on glucose
status, smoking status and use of anti-hypertensive
medication. Blood pressure was measured in a sitting
position at the right upper arm with a random-zero
sphygmomanometer and the average obtained of two
measurements at one occasion was used.
Blood sampling and storage have been described else-
where (24). Serum was separated by centrifugation and
quickly frozen in liquid nitrogen. For the present study,
we used blood measurements performed on fasting
blood samples. Glucose levels were measured by the
glucose hexokinase method (Medgenix Diagnostics,
Brussels, Belgium) with an intra-assay variation of
less than 2.5 and 6.0% respectively. Fasting insulin
was measured by a commercially available assay
(IRMA, Medgenix Diagnostics) with an intra- and
inter-assay variation of 3–6 and 5–12 percent,
respectively. Serum creatinine levels were assessed
using an automated enzymatic procedure (Roche,
Mannheim, Germany). Creatinine clearance was deter-
mined by the formula of Cockcroft and Gault (25).
Serum cholesterol and triglycerides were determined
by a standard laboratory method.
Participants collected timed overnight urine one day
before the examination, albumin and creatinine were
measured. Albumin and creatinine in urine were deter-
mined by a turbidimetric method and measured by a
Hitachi 917 analyzer (Roche/Hitachi Diagnostics,
Mannheim, Germany). Detection limit ranged from 2
to 400 mg/l and therefore all measurements below
2 mg/l were set at 1 mg/l. MA was defined as an albu-
min-to-creatinine ratio (ACR) of .2.5 mg/mmol in
males and 3.5 mg/mmol in females (26). From 34 sub-
jects, no data of MA were available. Fourteen subjects
(NGT: four subjects, AGT: ten subjects) met the criteria
for macroalbuminuria, they were included in the
analysis.
Genotyping of the IGF-I promoter
polymorphism
The human IGF-I gene contains a polymorphic CA
repeat 1 Kb upstream of the promoter region (27).
IGF-I genotypes were determined as described pre-
viously (17). The most common allele contains 19
CA-repeats, which equals a length of 192-bp (28). In
a previous study, we examined the role of the various
lengths of the alleles of the IGF-I promoter polymorph-
ism and observed an optimum for IGF-I levels and body
height (29). Mean IGF-I levels and body height
for homozygous carriers of the 192-bp allele, and
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homozygous carriers of the 194-bp-allele of this IGF-I
gene promoter polymorphism were equal and signifi-
cantly higher than the values measured in subjects
homozygous for alleles smaller than 192-bp and
longer than 194-bp, respectively, suggesting an opti-
mum for IGF-I expression by these two variants.
Based on carrier ship of the 192-bp and 194-bp alleles,
we therefore distinguished two different IGF-I geno-
types in the present study: As wild type genotype we
considered carriers homozygous for the 192-bp or for
the 194-bp allele, and carriers heterozygote for these
two alleles, participants with this genotype are further
in the text denoted as carriers of the wild type. Partici-
pants with all other combinations of alleles were con-
sidered carriers of the variant genotype, which is
further in the text denoted as variant carriers. Seven
hundred and eighty seven (73.6%) were carriers of
the wild type and 282 subjects were variant carriers
(26.4%).
Carotid ultrasonography
Carotid atherosclerosis was assessed by duplex scan
ultrasonography of the carotid arteries, using a
7.5 MHz linear array transducer (ATL, Ultramark IV).
Measurements of intima media thickness (IMT) were
performed offline from the still images recorded on
videotape. Details about this measurement have been
published previously (30). Briefly, the interfaces of the
far and near walls of the distal common carotid
artery are marked over a length of 10 mm. We used
the average of the measurements of three still images
of both the left and right arteries. Common carotid
IMT was determined as the mean IMT of near and far
wall measurements of both the left and right arteries.
Results from a reproducibility study of IMT measure-
ments have been published elsewhere(31). The mean
differences^S.D. in common carotid IMT between
paired measurements of sonographers, readers, and
visits were 20.004^0.10, 0.066^0.07, and
20.013^0.13 mm, respectively.
Data analyses
Except when otherwise mentioned, data are presented
as mean^S.D.Diabetic and non-diabetic groups were
compared with the Mann –Whitney test. Means of par-
ameters were compared between genotypes after strati-
fication for glucose tolerance using analyses of
variance. Insulin, albuminuria and ACR did not met
the criteria for normality and were logarithmic trans-
formed before analysis in order to obtain approximate
normal distribution. Therefore results of these par-
ameters are presented as geometric means with 95%
confidence intervals (CI). Distribution of sex, use of
antihypertensive drugs, lipid lowering drugs and fre-
quency of the metabolic syndrome between genotypes
was compared using a chi-square test.
Risk for MA was calculated by a binary logistic
regression analysis and all results are presented unad-
justed, and when explicitly mentioned, after adjustment
for age, sex, mean blood pressure, fasting glucose and
insulin levels and smoking. All analyses were per-
formed using the SPSS for Windows software package,
version 10.0.5 (SPSS Inc., Chicago, IL, USA).
Results
Table 1 presents clinical characteristics of 1069 sub-
jects (595 subjects with NGT and 474 subjects with
an AGT (254 subjects with pre-diabetes and 220 sub-
jects with diabetes) stratified by IGF-genotype. Subjects
with AGT were older and most of them were male in
comparison to subjects with NGT (Table 1). Serum
creatinine, blood glucose and cholesterol levels, blood
pressure and body mass index (BMI) were higher in
subjects with AGT than in subjects with NGT
(Table 1). Subjects with AGT frequently used more anti-
hypertensive drugs and had larger intima media ratios
and more insulin resistance than subjects with NGT.
There were no differences in general characteristics
between carriers of the wild type and variant carriers
of this IGF-I gene promoter polymorphism in the
group of NGT or AGT (Table 1).
Table 2 shows the relation between the two IGF-I gen-
otypes and parameters of renal function, comparing sub-
jects with AGT to subjects with NGT. Subjects with AGT
had significantly higher urinary albumin concentrations
and ACRs than subjects with NGT. In addition, mean
serum creatinine levels, creatinuria and clearance were
higher in subjects with AGT than in subjects with NGT.
In variant carriers with AGT, mean albuminuria and
ACR were higher than in carriers of the wild type, but
these differences did not reach statistical significance.
Subjects with an AGT had an increased risk of develop-
ing MA (Odds Ratio (OR): 2.5; 95% CI: 1.5–4.0;
P , 0.001) in comparison to subjects with NGT. Com-
pared to subjects with NGT, the risk for MA was higher
(OR: 3.1; 95% CI: 1.2 –7.7; P ¼ 0.02) in variant carriers
with AGT, than in carriers of the wild type of this IGF-I
gene polymorphism (OR: 2.2; 95% CI: 1.2 –4.0;
P ¼ 0.009; Fig. 1).
Table 3 shows the prevalence and relative risk of MA
in subjects with AGT and subjects with NGT stratified
for IGF-I genotype. Variant carriers with AGT had a
higher prevalence of MA than carriers of the wild
type of this IGF-I gene polymorphism, subsequently
the risk of MA for variant carriers was investigated.
In subjects with AGT, the relative risk for MA was
non-significantly increased in variant carriers when
compared with carriers of the wild type: (Relative
Risks (RR)): 1.5; 95% CI: 0.8 –2.9; P ¼ 0.19). When
this analysis was repeated after adjustment for age,
gender, fasting insulin, fasting glucose, mean blood
pressure and smoking, the risk of MA in variant
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carriers with AGT became significant: (RR: 2.1; 95%
CI: 1.1 –4.4; P ¼ 0.04). Compared with carriers of
the wild type genotype, the relative risk for MA also
increased in variant carriers with NGT after these
adjustments, but it still remained not significant (RR:
1.6; 95% CI: 0.6 –4.0; P ¼ 0.35).
Discussion
Compared to subjects with NGT, variant carriers with
AGT had a higher risk to develop MA than carriers of
the wild type genotype. In addition, variant carriers
with AGT had a borderline and significantly higher
prevalence of MA than carriers of the wild type geno-
type. This findings became significant after adjustment
for a number of possible confounding factors, which
have been previously found to be involved in the devel-
opment of MA. Our findings suggest that this IGF-I gene
polymorphism modulates the susceptibility and/or pro-
gression of MA as soon as a person develops AGT.
Compared with carriers of the wild type genotype,
we observed that the increased risk for MA in variant
carriers was relatively small. At first glance, this
suggests that the role of this IGF-I gene polymorphism
in the development of MA is not very important. How-
ever, the susceptibility to MA results probably from an
interaction of multiple genetic and environmental fac-
tors. Consequently, the relationship between the preva-
lence of MA (phenotype) and any individual causal
locus (genetic variant) will in general be fairly weak,
even for major genes. MA will only develop when cer-
tain other risk factors are also present, such as hyper-
glycemia, hypertension and/or smoking. This may
have obvious complications for both the number of sub-
jects in the study and the power of analyses that aim to
detect individual genetic signals among other genetic
and environmental background. This may explain
why we observed only a relative small and significant
increase in the risk of MA in variant carriers with
AGT, compared with carriers of the wild type genotype
Table 2 Relation between IGF-I genotype and parameters of renal function comparing subjects with NGT and subjects with AGT. Data
are mean (95% CI) unless otherwise stated.
NGT AGT
Wild type Variant carriers P2 Wild type Variant carriers P2 P1
Number of subjects 441 151 343 131
Albuminuria (mg/l)* 2.1 (1.9–2.4) 2.1 (1.8–2.5) 0.97 2.9 (2.5–3.3) 3.6 (2.9–4.7) 0.09 ,0.001
Creatininuria (mmol//l) 7.7 (7.4–8.1) 7.5 (6.8–8.1) 0.45 8.1 (7.7–8.6) 8.2 (7.5–8.9) 0.86 0.20
Albumin-to-creatinine ratio (mg/mmol)* 0.32 (0.29–0.37) 0.34 (0.28–0.40) 0.70 0.41 (0.35–0.48) 0.52 (0.40–0.66) 0.12 0.002
Creatinine (mmol/l) 89 (88–91) 89 (87–91) 0.93 92 (90–94) 91 (89–94) 0.61 0.27
Clearance (ml/min) 68 (66–69) 67 (65–69) 0.71 69 (68–71) 70 (67–72) 0.75 ,0.001
* Geometric Mean (95% CI); P1, P-value comparing subjects with NGT and subjects with AGT after adjustment for age and sex; P2, P-value comparing
wild type with variant carriers after adjustment for age and sex.
Table 1 General characteristics of the study population, comparing subjects with normal glucose tolerance (NGT) and subjects with
abnormal glucose tolerance (AGT) after stratification for IGF-I genotype.
NGT AGT
Wild type Variant type P2 Wild type Variant type P2 P1
Number of subjects 444 151 343 131
Age 66.2^5.6 66.0^4.8 0.67 67.7^5.8 66.8^5.8 0.11 ,0.001
Sex (M/F) 202/242 71/80 0.75 184/159 70/61 0.97 0.01
Creatinine (mmol/l) 89.3^15.0 89.4^13.9 0.93 92.2^18.0 91.0^17.9 0.61 0.27
Fasting glucose (mmol/l) 5.5^0.4 5.4^0.3 0.85 7.2^2.0 7.3^2.2 0.74 ,0.001
2-h glucose post-load (mmol/l) 5.3^1.2 5.3^1.2 0.76 9.4^3.9 9.2^4.0 0.67 ,0.001
Mean systolic bp (mmHg) 136^21 135^19 0.56 143^20 142^22 0.87 ,0.001
Mean diastolic bp (mmHg) 76^11 75^11 0.52 78^11 78^12 0.67 0.002
Total Cholesterol (mmol/l) 6.63^1.06 6.54^0.98 0.37 6.53^1.13 6.46^1.09 0.47 0.35
HDL-Cholesterol (mmol/l) 1.33^0.32 1.33^0.32 0.88 1.22^0.30 1.20^0.30 0.48 ,0.001
Triglycerides (mmol/l) 1.50^0.66 1.44^0.50 0.31 1.95^1.10 1.96^1.00 0.96 ,0.001
BMI (kg/m2) 25.8^3.1 26.0^3.3 0.69 27.5^3.6 27.4^3.7 0.73 ,0.001
Current smoking (%) 10.0 14.1 0.21 14.6 8.9 0.39 0.53
Antihypertensive drugs (%) 22.7 18.5 0.30 34.1 38.9 0.18 ,0.001
Lipid lowering drugs (%) 5.0 2.6 0.24 7.3 6.1 0.67 0.08
IMT (mm) 0.75^0.13 0.75^0.12 0.69 0.78^0.15 0.79^0.11 0.51 ,0.01
HOMA-IR 1.92^0.06 2.05^0.10 0.36 1.78^0.07 1.78^0.11 0.98 0.04
P1, P-value comparing Subjects with NGT and subjects with AGT after adjustment for age and sex; P2, P-value comparing wild type with variant type
adjusted for age and sex; HOMA-IR, homeostasis model assessment of insulin resistance.
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of this IGF-I gene polymorphism after adjustment for
some possible confounding factors.
The number of subjects with MA was low in our study
which might have further attributed to a reduced statisti-
cal power of our study. Although the prevalence of MA in
our study was low, this prevalence does not differ from
previous findings in another big Dutch population-
based study (32). In this latter study the prevalence of
MA was 6.6% in non-diabetic subjects and 16.1%
among diabetic patients. However, in this latter study,
the diagnosis of MA was exclusively based on urinary
albumin concentrations, while in our study this diagno-
sis was based on ACRs. A limitation of our study is that
MA was assessed on one overnight sample. It is well
known that there is considerable intra-individual varia-
bility in urinary albumin excretion in time (33). As a
consequence, the prevalence of MA in our study may
have been significantly both underestimated as well as
overestimated.
Another limitation of our study may be that there is
not only an age-related penetrance of AGT, but also an
age-related penetrance of MA. Subjects with a NGT at
the time of the study may still develop both an altered
glucose tolerance and MA in the near future. We pre-
viously observed that variant carriers of this IGF-I
gene polymorphism have an increased risk of develop-
ing diabetes, in comparison to carriers of the wild
type genotype. Thus, this suggests that especially in
variant carriers with AGT, the risk for MA may have
been underestimated. Moreover, the diagnostic
umbrella MA probably gathers individuals who have
developed MA through a variety of pathological mech-
anisms (see below). This has obvious implications for
the interpretation of our findings.
We did not find relationships between this IGF-I gene
promoter polymorphism and renal function parameters,
this was not unexpected. In subjects with type 2 diabetes
MA is generally considered a stronger predictor of cardi-
ovascular disease than it is of the risk of end-stage renal
failure (34). Type 2 diabetes patients with MA are at an
increased risk of cardiovascular death compared with
patients with normal albuminuria (35, 36). In addition,
in non-diabetic subjects, MA is even considered an inde-
pendent risk factor to developing cardiovascular disease
(3, 32). The observed relationship between IGF-I geno-
type and MA in our study thus probably points mainly
to an increased risk of variant carriers for cardiovascular
disease. This is in accordance with our previous findings:
we observed that variant carriers had a higher risk of
developing myocardial infarction (17). In addition, caro-
tid IMT and aortic pulse wave velocity were significantly
increased in variant carriers with hypertension (37).
MA may be the first sign that the vascular vessel
wall, particularly the endothelium, is injured. It has
been found that MA can be the specific consequence
of a reduction in the fixed negative charges of the glo-
merular wall (38, 39).Whether an IGF-I gene genotype
of a subject may modulate the susceptibility and/or pro-
gression of MA by circulating IGF-I or rather via its
effects at the tissue level is at present unknown. How-
ever, it is likely that a link should be found in altera-
tions in the composition of the basal membranes of
the capillaries and of the extracellular matrices,
which has also has been hypothesized for type 1
diabetes.
When our findings will have been replicated by
others, these observations may suggest the existence
of new etiological pathways for the development of
MA, and together, provide some prediction of who
will or will not get MA. In addition, it has been
suggested that even if the risk is imparted by a certain
genotype is low, or that only a subset of subjects carry
the predisposing genotype, modulation of that gene by
pharmacological intervention may be beneficial (40).
In conclusion, we observed in patients with AGT had
a higher risk for MA in variant carriers than in carriers
of the wild type genotype of this IGF-I gene promoter
polymorphism. Since MA is primarily associated with
cardiovascular disease in subjects with type 2 diabetes,
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Figure 1 The relative risk of microalbuminuria comparing subjects
with NGT and AGT per IGF-I genotype (wild type, left; variant car-
riers, right). Individuals with NGT were used as the reference
group. *P ¼ 0.009, **P ¼ 0.02 vs the reference group.
Table 3 The relative risk of microalbuminuria of subjects with
AGT and subjects with NGT stratified by IGF-I genotype. Number
of subjects for each category are given (% of cases or controls).
Risks are given with a 95% confidence interval between brackets.
Wild type Variant type
Subjects with AGT
Microalbuminuria 31 (9.3%) 17 (13.5%)
No microalbuminuria 303 (90.7%) 109 (86.5%)
Relative risk Reference 1.5 (0.8–2.9)*
Relative risk Reference 2.1 (1.0–4.4)**
Subject with NGT
Microalbuminuria 19 (4.4%) 7 (4.8%)
No microalbuminuria 410 (95.6%) 139 (95.2%)
Relative risk Reference 1.1 (0.45–2.64)*
Relative risk Reference 1.6 (0.61–4.03)**
*Unadjusted; **After further adjustment for age, gender, mean blood press-
ure, fasting glucose, fasting insulin and smoking.
IGF-I polymorphism and microalbuminuria 719EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006) 154
www.eje-online.org
our study suggests that variant carriers with an AGT
have an increased risk for cardiovascular disease.
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